title: The role of thymosin-β4 in kidney disease.
abstract: Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.
authors.affiliation: UCL Institute of Child Health, Developmental Biology and Cancer , 30 Guilford Street, London, WC1N 1EH , UK +44 207 905 2615 ; +44 207 905 2133 ; d.long@ucl.ac.uk.
authors.forename: Elisavet
authors.initials: E
authors.lastname: Vasilopoulou
authors.forename: Paul J D
authors.initials: PJ
authors.lastname: Winyard
authors.forename: Paul R
authors.initials: PR
authors.lastname: Riley
authors.forename: David A
authors.initials: DA
authors.lastname: Long
mesh_terms: D000328:Adult; D000818:Animals; D005355:Fibrosis / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D051379:Mice; D051381:Rats; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000235:genetics*; D013947:Thymosin / Q000502:physiology* / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects / Q000235:genetics; D000099201:Thymosin beta(4)
chemical_list: D013947:Thymosin; D000099201:Thymosin beta(4)
keywords: Ac-SDKP; fibrosis; inflammation; kidney disease; thymosin-β4